| CD4 | CD317 | HIV-1 Release |
---|
| Downregulationa | Downregulationa | Degradationb | Enhancementc |
---|
Vpu | + | + | + | + |
VpuS52/56A | - | - | - | - |
Vpu + β-TrCP1 wt |
+
|
+
|
+
|
+
|
Vpu + β-TrCP1ΔFbox | - | - | - | - |
Vpu + β-TrCP1 KDd |
+
|
+
|
+
|
+
|
Vpu + β-TrCP2 KDd | - |
+
| - |
+
|
Vpu + β-TrCP1/2 KDd | - |
+
| n.a. |
+
|
- aVpu-mediated downregulation of CD4 and CD317 from the surface of HIV-1-infected or transfected cells was quantified by flow cytometry (Figures. 1E-G; 2C, D; 4C; 8D)
- bVpu-mediated depletion of CD317 in HIV-1-infected or transfected cells was analyzed by quantitative immunoblotting (Figures. 1B; 2B) and/or immunofluorescence microscopy (Figures. 1C, D; 2E-F; 3A, B; 5B, C; 8B, C)
- cThe ability of Vpu to overcome the CD317-mediated HIV-1 release restriction was analyzed by quantification of infectious virus in culture supernatants (Figures. 1A; 2A; 3A, 5A; 8A)
- dKD: siRNA-mediated knockdown (verified by RT-PCR)
- n.a.: not analyzed